TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02292966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCV/ASV/BCV
Description: Each participant will each receive daclatasvir (30mg), asunaprevir (200mg) and beclabuvir (75mg) in a fixed-dose combination oral tablet for twice daily administration with food.
Study: NCT01974388

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LSG started 2 cm from the pylorus
Description: Laparoscopic sleeve gastrectomy started 2 cm from pylorus

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LSG started 6 cm from pylorus
Description: LSG started 6 cm from pylorus
Study: NCT03201913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTC-352
Description: Phase 1 study to determine the maximum tolerated dose (MTD) of TTC-352.
Study: NCT02607449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FS-1
Description: FS-1 is a liquid solution for internal intake and has antimicrobial and antibacterial activities.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo without any active pharmaceutical ingredients
Study: NCT00356616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trizivir (AZT+3HT+Abacavir) twice daily
Description: Trizivir (AZT+3HT+Abacavir) twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Viread (300 mg Tenofovir disoproxil fumarate) once daily
Description: Viread (300 mg Tenofovir disoproxil fumarate) once daily
Study: NCT00894686

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FSME-IMMUN 0.25 mL Junior (1.2 µg TBE antigen/0.25 mL) or FSME-IMMUN 0.5 mL (2.4µg TBE antigen/0.5 mL)
Description: Dosage form: solution/suspension; injectable. Dosage frequency: once. Mode of administration: intramuscular.
Study: NCT03059927

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Knee arthroplasty, Cruciate retaining
Description: Legion total knee arthroplasty implant component, Smith \& Nephew, Cruciate Retaining design

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Knee arthroplasty, Anterior stabilized
Description: Legion total knee arthroplasty implant component, Smith \& Nephew, Anterior Stabilized design

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Knee arthroplasty, Posterior stabilized
Description: Legion total knee arthroplasty implant component, Smith \& Nephew, Posterior Stabilized design
Study: NCT00943020

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutricia PreOp nutritional supplement
Description: nutritional supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutricia PreOp nutritional supplement
Description: nutritional supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutricia PreOp nutritional supplement
Description: nutritional supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lipid
Description: Drink

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glutamine
Description: Drink
Study: NCT02341703

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: letrozole-metformin
Description: letrozole 2.5 mg will be given daily from day 3 of the cycle for 5 days + metformin 500 mg three times daily continuously for 3 months unless pregnancy occurred

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: letrozole-metformin-pioglitazone
Description: letrozole will be given daily from day 3 of the cycle for 5 days + (metformin 850 mg + pioglitazone 15 mg) from the first day of the cycle for 10 days.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: transvaginal ultrasound
Description: transvaginal ultrasound will be done from day 10 of the cycle and every other day for monitoring of follicular enlargement.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: transvaginal ultrasound
Description: transvaginal ultrasound will be done from day 10 of the cycle and every other day for monitoring of follicular enlargement.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory investigations
Description: day 3: FSH, LH, TSH, and total testosterone day 12 serum E2 day 21 serum progesterone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory investigations
Description: day 3: FSH, LH, TSH, and total testosterone day 12 serum E2 day 21 serum progesterone
Study: NCT04119141

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: X ray imaging
Description: Acquisition:~* 140 kVp,~* 1/2 mAs/kg,~* Pitch: 1.35,~* Rotation time: 0.5 sec.~Reconstruction:~* I70f filter, 3 iteration loops,~* Cutting thickness 1 mm/0.7 mm~* Fenestration: C -600/W 1600~* Field of view (Size, x \& y coordinates) identical on both acquisitions.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: X ray imaging
Description: Acquisition:~* 140 kVp,~* 1/2 mAs/kg,~* Pitch: 1.35,~* Rotation time: 0.5 sec.~Reconstruction:~* I70f filter, 3 iteration loops,~* Cutting thickness 1 mm/0.7 mm~* Fenestration: C -600/W 1600~* Field of view (Size, x \& y coordinates) identical on both acquisitions.
Study: NCT01923350

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Reduction Intervention
Description: The weight trial intervention components were:~* Electronic feedback from the ADAPT interactive obesity treatment approach (iOTA) system, tracking participants' behavior change goals. Participants received feedback either by daily SMS (text messaging) or by weekly IVR (interactive automated calls).~* Seven behavior change coaching calls, once a month for 6 months, and then one at 7.5 months halfway through the maintenance period.~* Print mailings/emailings~* 3 Get Ready e-messages in the four weeks before the weight intervention began~* Pedometers and program guides. (IVR users received printed activity logs with their program guides.)~* Access to the ADAPT iOTA website for reviewing their progress and obtaining information on behavior change goals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Reduction Control Arm
Description: Participants received an initial brochure about managing diabetes risk, a digital scale to use in entering their weights in online questionnaires, and monthly emailed wellness messages unrelated to diabetes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tested for diabetes
Description: Due to small numbers in this group, the planned intervention was changed to a mixed-mode study, using baseline and follow-up self-administered questionnaires and semi-structured questionnaires administered to a sub-sample of those tested for diabetes to identify factors differentiating the behavior of women who had and had not been tested for diabetes following a pregnancy with gestational diabetes mellitus.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Not tested for diabetes
Description: Due to small numbers in this group, the planned intervention was changed to a mixed-mode study, using baseline and follow-up self-administered questionnaires and semi-structured questionnaires administered to a subsample of those not tested for diabetes to identify factors differentiating the behavior of women who had and had not been tested for diabetes following a pregnancy with gestational diabetes mellitus.
Study: NCT03948360

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-Irradiance Monochromatic Biostimulation (LIMB) Device
Description: The LIMB System is a portable and wearable phototherapeutic system that consists of a Light Patch and Power Pack. The Power Pack delivers power to the Light Patch, which attaches to the participant and emits blue spectrum (405nm low-irradiance) light. The Light Patch contains an array of thin optical arrays that evenly illuminate the surface. The Power Pack is powered by a Lithium Thionyl Chloride (Li-SOCI2) battery.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-Irradiance Monochromatic Biostimulation (LIMB) Device
Description: The LIMB System is a portable and wearable phototherapeutic system that consists of a Light Patch and Power Pack. The Power Pack delivers power to the Light Patch, which attaches to the participant and emits blue spectrum (405nm low-irradiance) light. The Light Patch contains an array of thin optical arrays that evenly illuminate the surface. The Power Pack is powered by a Lithium Thionyl Chloride (Li-SOCI2) battery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care therapy as defined for this clinical trial is standard gauze dressing soaked in Sulfamylon (mafenide acetate) solution.
Study: NCT00757003

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular Stent-graft repair of descending thoracic aorta
Description: A TAG device will be used to repair the pathology in the thoracic aorta
Study: NCT02673606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol 2Mg Tablet
Description: one 2 mg dose of estradiol (obtained from Estrace® Tablets, 2.0 mg estradiol tablets, USP, Warner Chilcott),

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol 4Mg Tablet
Description: two 2 mg pills estradiol(obtained from Estrace® Tablets, 2.0 mg estradiol tablets, USP, Warner Chilcott),

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Pills
Description: inactive placebo pills
Study: NCT04394481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: IV injection (1 µg/kg - 100 mL) before anesthetic induction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Perinervous injection between C5 and C6 nerve roots / interscalene block (0.75% - 20 mL)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Perinervous injection between C5 and C6 nerve roots / interscalene block (0.75% - 20 mL)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: IV injection (0.15 mg/kg) during anesthetic induction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: IV injection (0.15 mg/kg) during anesthetic induction
Study: NCT01069250

Intervention type: OTHER
Intervention: There are no interventions in this study
Study: NCT02992314

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Metaqil™ Oral Rinse
Description: Metaqil™ is a proprietary formulation of GRAS ingradients

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo formulation with out the active ingredients
Study: NCT03684642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efpeglenatide
Description: Pharmaceutical form: solution for injection; Route of administration: SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efpeglenatide
Description: Pharmaceutical form: solution for injection; Route of administration: SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dulaglutide
Description: Pharmaceutical form: solution for injection; Route of administration: SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Background therapy Metformin
Description: Pharmaceutical form: tablet; Route of administration: oral; Dose to be kept stable throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background therapy Metformin
Description: Pharmaceutical form: tablet; Route of administration: oral; Dose to be kept stable throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background therapy Metformin
Description: Pharmaceutical form: tablet; Route of administration: oral; Dose to be kept stable throughout the study.
Study: NCT04120610

Intervention type: DIAGNOSTIC_TEST
Intervention: FlowMet-R
Description: FlowMet-R is a noninvasive blood flow measurement.

Intervention type: DIAGNOSTIC_TEST
Intervention: FlowMet-R
Description: FlowMet-R is a noninvasive blood flow measurement.

Intervention type: DIAGNOSTIC_TEST
Intervention: ABI
Description: Ankle Brachial Index is a ratio-metric blood pressure measurement in the ankle and arm.

Intervention type: DIAGNOSTIC_TEST
Intervention: ABI
Description: Ankle Brachial Index is a ratio-metric blood pressure measurement in the ankle and arm.

Intervention type: DIAGNOSTIC_TEST
Intervention: TBI
Description: Ankle Brachial Index is a ratio-metric blood pressure measurement in the toe and arm.

Intervention type: DIAGNOSTIC_TEST
Intervention: TBI
Description: Ankle Brachial Index is a ratio-metric blood pressure measurement in the toe and arm.
Study: NCT02407470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabbit antithymoglobulin (ATG)
Description: Rabbit ATG at 3.5 mg/kg/dose IV is given from day -6 to -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabbit antithymoglobulin (ATG)
Description: Rabbit ATG at 3.5 mg/kg/dose IV is given from day -6 to -2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabbit antithymoglobulin (ATG)
Description: Rabbit ATG at 3.5 mg/kg/dose IV is given from day -6 to -2.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adipose derived mesenchymal stem cells ( AD-MSCs)
Description: Participants will receive rabbit ATG at 3.5 mg/kg/dose IV from day -6 to -2, and then patient's own AD-MSCs at a dose of 3000000 cells/kg/d on day 1-3.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AD-MSC transdifferentiated HSCs (AD-HSCs)
Description: Participants will receive rabbit anti-thymocyte globulin at 3.5 mg/kg/dose IV from day -6 to -2, and then patient's own AD-HSCs at a dose of 3000000 cells/kg/d from day 1 to 4.
Study: NCT05881174

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: acupuncture

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: acupuncture

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: acupuncture
Study: NCT01067755

Intervention type: DEVICE
Intervention: LungPoint Virtual Bronchoscopic Navigation (computer-assisted image-guided bronchoscopic navigation)
Description: LungPoint Virtual Bronchoscopic Navigation is a product that displays images and information to aid bronchoscopists in guiding the bronchoscope and other instruments to a target location in the lung airways.
Study: NCT00265603

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Photochemotherapy With Transimmunization
Description: The photopheresis apparatus and procedure will be identical to that currently used. Patients will receive intravenous 8-MOP (UVADEX®) directly into the photopheresis apparatus, to yield a concentration of 50-200 ng/ml of drug. The blood will be leukapheresed to obtain a buffy coat and will then be passed through the contiguous closed circuit ultraviolet A exposure device, delivering the desired 1-2 joules/cm2 of ultraviolet A energy. In this manner 2-4 molecules of 8-MOP will be induced to bind covalently to thymines of the leukocyte DNA. At that point, the single variation from the standard treatment will be initiated. Instead of returning the patient's cells and the saline to the patient, the bag will be detached from the apparatus. KLH (depyrogenated, endotoxin-free; Calbiochem-Novabiochem Corp., San Diego, CA) will be added at a concentration of 10 g/ml to the DC-rich leukocyte culture prior to overnight culture.
Study: NCT03618784

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FURESTEM-RA Inj
Description: The allogeneic umbilical cord blood-derived mesenchymal stem cells of each dose level as below were mixed into an IV bag containing 100 ml of sterile saline solution and the IV bag was gently massaged to obtain homogeneous mixture of the cell suspension.~Administer the constituted cell suspension by IV infusion to a subject. The infusion should be completed in 60 minutes using infusion pump.~* Dose level 1: 5.0 x 10\^7 cells /body 3 repeated intravenous injection at 4 week intervals~* Dose level 2: 1.0 x 10\^8 cells /body 3 repeated intravenous injection at 4 week intervals

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sterile saline
Description: sterile saline 3 repeated intravenous injection at 4 week intervals~Placebo were mixed into an IV bag containing 100 ml of sterile saline solution and the IV bag was gently massaged to obtain homogeneous mixture of the cell suspension.~Administer the constituted cell suspension by IV infusion to a subject. The infusion should be completed in 60 minutes using infusion pump.
Study: NCT02179671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Gefitinib once daily followed by MEDI4736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291
Description: AZD9291 once daily followed by MEDI4736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib+Docetaxel
Description: Selumetinib twice daily + docetaxel, followed by MEDI4736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab every 4 weeks followed by MEDI4736
Study: NCT03277326

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ISB
Description: ISB block with 0.5% ropivicaine 15mls ( 45mg )

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: aSSB
Description: aSSB block with 0.5% ropivicaine 15mls ( 45mg )

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pSSB
Description: pSSB block with 0.5% ropivicaine 15mls ( 45mg )
Study: NCT03602274

Intervention type: DIAGNOSTIC_TEST
Intervention: Hepatic function monitoring
Description: AST, ALT, GGT, AP, Bilirubin

Intervention type: DIAGNOSTIC_TEST
Intervention: Hepatic function monitoring
Description: AST, ALT, GGT, AP, Bilirubin

Intervention type: DIAGNOSTIC_TEST
Intervention: Nutritional status assesment
Description: PINI, MNA nutritional assessment, PG-SGA assessment, anthropometric measurements

Intervention type: OTHER
Intervention: Biomarker research sampling
Description: Blood collection for proteomic, genetic, metabolomic and microRNA transcriptomic profiling

Intervention type: OTHER
Intervention: Biomarker research sampling
Description: Blood collection for proteomic, genetic, metabolomic and microRNA transcriptomic profiling
Study: NCT04118296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Acne Preparations for Topical Use
Description: Combination of anti acne cream that contain active substances such as Clindamycin 3%, Dexamethasone 0.05% and Tretinoin 0.05%
Study: NCT01141088

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral stent-in-stent insertion
Description: Following negotiation of both IHD by two guidewires, inserted 1st stent to left IHD side. After deployment of the 1st stent across the hilar stricture, the remaining guide wire across the 1st stent was carefully withdrawn using an ERCP catheter without pulling it back completely. Then that guidewie was inserted under fluoroscopic guidance into the undrained right IHD through the central portion of the 1st stent. The 2nd cross-wired stent was then introduced over a guidewire through the central open mesh and then was deployed into the right IHD, so that the central portion of the 2nd stent overlapped the central portion of the 1st stent, forming a Y-shape.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral stent-in-stent insertion
Description: Following negotiation of both IHD by two guidewires, inserted 1st stent to left IHD side. After deployment of the 1st stent across the hilar stricture, the remaining guide wire across the 1st stent was carefully withdrawn using an ERCP catheter without pulling it back completely. Then that guidewie was inserted under fluoroscopic guidance into the undrained right IHD through the central portion of the 1st stent. The 2nd cross-wired stent was then introduced over a guidewire through the central open mesh and then was deployed into the right IHD, so that the central portion of the 2nd stent overlapped the central portion of the 1st stent, forming a Y-shape.
Study: NCT03583892

Intervention type: DRUG
Intervention: Gabapentin
Description: One of the groups of patients was exposed to preoperative gabapentin. As the pain has a complex involvement of multiple mechanisms, multimodal analgesic techniques utilizing a number of drugs acting on different analgesic mechanisms are being used. In this case, some patients received gabapentin as a part of a multimodal analgesic technique.
Study: NCT00831181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU: continuous infusion via portable pump during all RT (approximately 33 days)
Study: NCT01141088

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral side-by-side insertion
Description: Following the introduction of two guidewires, the first stent was pushed and deployed into the left hepatic duct as possible, and then subsequently the second stent was pushed and deployed into the right hepatic duct, using the same method. In tight stricture during a guidewire manipulation, pneumatic biliary balloon dilation prior to insertion of first stent was performed. All stents were positioned above the level of the papilla, with their distal ends at the same level as possible. The diameter of the stent used in each case (8 or 10 mm) depended on the maximum diameter of the common bile duct (CBD).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral side-by-side insertion
Description: Following the introduction of two guidewires, the first stent was pushed and deployed into the left hepatic duct as possible, and then subsequently the second stent was pushed and deployed into the right hepatic duct, using the same method. In tight stricture during a guidewire manipulation, pneumatic biliary balloon dilation prior to insertion of first stent was performed. All stents were positioned above the level of the papilla, with their distal ends at the same level as possible. The diameter of the stent used in each case (8 or 10 mm) depended on the maximum diameter of the common bile duct (CBD).
Study: NCT00839943

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ozone, 0.4 ppm
Description: 2 hour ozone exposure, 0.40 ppm

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ozone, 0.4 ppm
Description: 2 hour ozone exposure, 0.40 ppm
Study: NCT02052063

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stapled transanal rectal resection
Description: transanal rectal resection using staple will be done for rectocele

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anal compliance measure with Endoflip system
Description: Anal compliance will be measured using Endoflip system
Study: NCT04418544

Intervention type: DEVICE
Intervention: Device used to record voice for screening
Description: voice recording

Intervention type: DEVICE
Intervention: Device used to record voice for screening
Description: voice recording
Study: NCT05099653

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical activity
Description: physical activity